At present, there is no official unified standard for the price of Tunlametinib Capsules (Keluping) in the 6mg strength. The specific price may vary due to factors such as region, hospital and medical insurance policy. It is recommended to consult local formal hospitals or medical insurance-designated pharmacies for accurate information.
1. Basic Drug Information
Tunlametinib is a Class 1 innovative drug independently developed in China, mainly used for the treatment of melanoma associated with specific gene mutations (such as NRAS mutation). The drug was first launched in Chinese Mainland on March 12, 2024, under the trade name "Keluping", with two specifications: 3mg and 6mg.
2. Price Reference & Influencing Factors
According to some publicly available information, the price of Tunlametinib Capsules may be in the range of several thousand yuan. For example, feedback shows that the price of the 3mg strength (56 capsules) is about USD 1,204, but the specific pricing of the 6mg strength shall be subject to the actual purchasing channel. The price is affected by the following factors:
Regional differences
Medical insurance reimbursement policies and hospital procurement prices may vary in different provinces and cities;
Medical insurance coverage
If the drug has been included in the National Medical Insurance Catalog, patients can enjoy partial reimbursement;
Purchase channels
It is necessary to purchase through formal hospitals or designated pharmacies to avoid irregular channels.
3. Usage Advice & Precautions
Dosage and administration
It shall be taken orally strictly as prescribed by the doctor, usually twice a day, and the specific dosage shall be adjusted according to the patient's condition;
Medical insurance inquiry
It is recommended to consult the doctor or the hospital's medical insurance office about reimbursement policies and out-of-pocket ratios during the visit;
Authorized channels
Be sure to purchase through public hospitals or authorized pharmacies to ensure pharmaceutical quality and medication safety.
